Healthcare Industry News:  influenza 

Diagnostics Distribution

 News Release - February 28, 2008

Luminex and Abbott Sign Agreement for Global Distribution of the xTAG(TM) Respiratory Viral Panel

Abbott to Sell and Distribute New Breakthrough Test

AUSTIN, Texas--(HSMN NewsFeed)--Luminex Molecular Diagnostics, a division of Luminex Corporation (NASDAQ: LMNX ), the worldwide leader in multiplexing solutions, has signed a global sales and distribution agreement with Abbott’s (NYSE: ABT ) molecular diagnostics business. Under the terms of the agreement, Abbott will have exclusive rights to distribute Luminex’s new xTAGTM Respiratory Viral Panel (RVP) worldwide outside the United States and semi-exclusive rights in the United States.

Based on Luminex’s xMAP® multiplexing technology, xTAG RVP was created by Luminex Molecular Diagnostics, in partnership with a team of leading virologists and infectious disease specialists. In a matter of hours from a single patient sample, the test allows doctors to detect the presence or absence of several viruses and subtypes at once.

“We believe that xTAG RVP has the potential to significantly impact the detection, treatment, and control of respiratory viruses worldwide,” said Douglas Bryant, executive vice president and chief operating officer of Luminex. “Abbott’s long-standing dedication to improve the quality of human health, combined with their global customer base, will make them a strong partner in bringing xTAG RVP to more physicians, public health authorities and patients around the world.”

xTAG RVP received 510(k) clearance by the U.S. Food and Drug Administration in January 2008, and became CE marked for sale in Europe in November 2006.

In the United States, xTAG RVP has been cleared to detect 12 viruses and viral subtypes:

Adenovirus
influenza A (all subtypes)
influenza A H1
influenza A H3
influenza B
Metapneumovirus
Parainfluenza 1
Parainfluenza 2
Parainfluenza 3
Respiratory syncytial virus (RSV) A
Respiratory syncytial virus (RSV) B
Rhinovirus

In Europe, xTAG RVP is certified to detect and identify 20 viruses and viral subtypes – including the targets above, plus:

Corona Virus 229E
Corona Virus HKU1
Corona Virus NL63
Corona Virus OC43
Enterovirus
influenza A H5
Parainfluenza 4
SARS

For more information on the xTAG RVP, please visit www.luminexcorp.com/rvp.

About Luminex Corporation

Luminex Corporation develops, manufactures and markets proprietary biological testing technologies with applications throughout the diagnostic and life sciences industries. The Company's xMAP® multiplex solutions include an open-architecture, multi-analyte technology platform that delivers fast, accurate and cost-effective bioassay results to markets as diverse as pharmaceutical drug discovery, clinical diagnostics and biomedical research, including the genomics and proteomics research markets. The Company's xMAP technology is sold worldwide and is already in use in leading clinical laboratories as well as major pharmaceutical, diagnostic and biotechnology companies. Further information on Luminex Corporation or xMAP technology can be obtained at www.luminexcorp.com.


Source: Luminex Molecular Diagnostics

Issuer of this News Release is solely responsible for its content.
Please address inquiries directly to the issuing company.



FindReps 2 - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps 2 - available on the Apple App Store for iPhone and iPad.